Clinical Trials
202 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
LEARN
University of Sydney
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
University of Colorado, Denver
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
iCaRe2
University of Nebraska
DP-04
AstraZeneca
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
Memorial Sloan Kettering Cancer Center
ReRT
The New York Proton Center
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
MOMENTUM
UMC Utrecht
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
ONE TEAM
Duke University
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
GUARDIAN-101
Clasp Therapeutics, Inc.
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
BCB RIV
Institut du Cancer de Montpellier - Val d'Aurelle
PharmTRT
Hospices Civils de Lyon
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
TAGNOT
Kidney Cancer Research Bureau
CAMPERR
Adela, Inc
SCORE
Natera, Inc.
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
P-MRI
University of Michigan
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
PETRiS
XEOS Medical
DETERMINE
Cancer Research UK
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
ENGAGE
Maastricht Radiation Oncology
EARN
Washington University School of Medicine
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
3B Pharmaceuticals GmbH
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
FASCINATE
The Netherlands Cancer Institute